股票 › GENB
生成生物医药 GENB
美股市值排名 #2859
$13.06 +$0.49 (+3.90%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $13.06 0.00%
开盘$12.90
昨收$12.57
当日区间$12.47 – $13.17
成交量632.2K
市值$1.68B
市盈率（TTM）–
股息率–
基本面
最新报告季度：Q2, ended Jun 2026
营收$6.31M-37.7% YoY
营业利润-$71.61M-19.1% YoY
净利润-$67.26M-18.5% YoY
摊薄每股收益-$0.52+16.9% YoY
自由现金流-$58.88M-20.4% YoY
经营现金流-$57.94M
营收，近4个季度
净利润，近4个季度
各季度摊薄每股收益
各季度自由现金流
盈利能力与资产负债表
营业利润率-991.2%
净利率-1,014.5%
净资产收益率-58.9%
资产收益率-47.8%
投入资本回报率-53.2%
流动比率8.30
负债/资产比率18.8%
现金及投资$457.42M
总负债$49.01M
净现金（净负债）$408.41M
资产负债表
| 项目 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2024 ANNUAL |
|---|---|---|---|---|
| -现金及现金等价物 | $135.36M | $160.58M | $121.65M | $176.27M |
| 其他非流动资产 | $9.06M | $4.75M | $6.81M | $9.70M |
| 现金及现金等价物与短期投资 | $457.42M | $516.64M | $221.50M | $393.63M |
| 流动资产合计 | $470.25M | $535.39M | $234.37M | $407.49M |
| 总资产 | $561.69M | $625.74M | $330.18M | $518.26M |
| -短期投资 | $322.06M | $356.07M | $99.85M | $217.36M |
| 短期债务及融资租赁负债 | $13.62M | $14.26M | $15.01M | $16.72M |
| 少数股东权益 | $0.00 | $0.00 | -$7.23M | -$571,000.00 |
| 不影响留存收益的损益 | -$129,000.00 | $24,000.00 | $106,000.00 | $118,000.00 |
| 留存收益 | -$804.99M | -$737.74M | -$676.29M | -$473.14M |
| 资本公积 | $1.26B | $1.25B | $60.19M | $38.47M |
| -普通股 | $128,000.00 | $128,000.00 | $33,000.00 | $33,000.00 |
| 股本 | $128,000.00 | $128,000.00 | $33,000.00 | $33,000.00 |
| 股东权益合计 | $456.05M | $514.80M | -$623.20M | -$435.09M |
| 可转换优先证券 | $0.00 | $0.00 | $811.83M | $789.85M |
| 一年以上递延负债 | $0.00 | $1.24M | $4.51M | $15.17M |
| 衍生产品负债 | $0.00 | $0.00 | $1.21M | $1.09M |
| -长期融资租赁负债 | $49.01M | $51.31M | $53.52M | $60.26M |
| 长期债务及融资租赁负债 | $49.01M | $51.31M | $53.52M | $60.26M |
| 股东权益 | $456.05M | $514.80M | -$615.97M | -$434.52M |
| 非流动负债合计 | $49.01M | $52.55M | $871.18M | $866.72M |
| 其他流动负债 | $2.52M | $2.42M | $2.63M | $2.43M |
| 其他流动资产 | $12.84M | $18.75M | $12.53M | $12.13M |
| 非流动资产合计 | $91.44M | $90.35M | $95.82M | $110.77M |
| 固定资产净值 | $82.38M | $85.60M | $89.01M | $101.07M |
| -固定资产原值 | $137.13M | $137.13M | $137.27M | $136.24M |
| 一年内应计费用 | $14.70M | $12.50M | $25.74M | $6.03M |
| -应付账款 | $5.65M | $7.62M | $3.84M | $5.67M |
| 应付款 | $5.65M | $7.62M | $3.84M | $5.67M |
| 负债合计 | $105.65M | $110.94M | $953.38M | $953.35M |
| -累计折旧 | -$54.75M | -$51.53M | -$48.26M | -$35.17M |
| 流动负债合计 | $56.64M | $58.39M | $82.20M | $86.63M |
| 受限现金 | $0.00 | $0.00 | $339,000.00 | $1.43M |
| -一年内到期融资租赁负债 | $13.62M | $14.26M | $15.01M | $16.72M |
| 一年内递延负债 | $12.17M | $17.24M | $21.19M | $42.43M |
| 应收款 | – | – | $0.00 | $308,000.00 |
| -应收账款 | – | – | $0.00 | $308,000.00 |
| 其他非流动负债 | – | – | $116,000.00 | $349,000.00 |
现金流量表
| 项目 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| 筹资活动现金流 | -$579,000.00 | $378.89M | $28.06M | -$263,000.00 | $20.56M |
| 投资购置及出售净额 | $34.24M | -$256.15M | $120.28M | -$16.91M | $76.28M |
| 固定资产购置及出售净额 | -$933,000.00 | -$3.78M | -$3.51M | -$154,000.00 | -$751,000.00 |
| 持续经营投资活动现金流净额 | $33.31M | -$259.93M | $116.77M | -$17.07M | $75.53M |
| 持续经营筹资活动现金流净额 | -$579,000.00 | $378.89M | $28.06M | -$263,000.00 | $20.56M |
| 普通股发行净额 | $0.00 | $369.29M | – | $0.00 | $0.00 |
| 期末现金余额 | $139.39M | $164.61M | $126.04M | $158.66M | $224.75M |
| 自由现金流 | -$58.88M | -$84.17M | -$204.13M | -$48.91M | -$53.93M |
| 期初现金余额 | $164.61M | $126.04M | $181.83M | $224.75M | $181.83M |
| 现金净变动 | -$25.21M | $38.57M | -$55.79M | -$66.08M | $42.92M |
| -应付账款及应计费用变动 | $2.21M | -$17.30M | $15.24M | $7.27M | -$7.00M |
| 其他筹资费用净额 | $0.00 | $7.50M | $13.15M | $2.00M | $750,000.00 |
| 股票期权行使所得 | $414,000.00 | $3.22M | $1.10M | $154,000.00 | $483,000.00 |
| 优先股发行净额 | $0.00 | $0.00 | $21.97M | -$1,000.00 | $21.97M |
| -其他营运资金变动 | -$6.31M | -$7.22M | -$31.89M | -$10.13M | -$8.82M |
| -其他流动负债变动 | -$1.95M | -$1.96M | -$2.94M | -$114,000.00 | -$172,000.00 |
| -其他流动资产变动 | -$4.31M | $2.05M | $4.84M | $1.89M | $1.40M |
| -预付资产变动 | $5.91M | -$6.22M | -$166,000.00 | -$338,000.00 | -$2.76M |
| -应收款变动 | $0.00 | $0.00 | $308,000.00 | $59,000.00 | -$91,000.00 |
| 营运资金变动 | -$4.46M | -$30.65M | -$14.62M | -$1.36M | -$17.44M |
| 其他非现金项目 | $2.69M | $2.09M | $5.94M | $1.34M | $1.34M |
| 折旧、折耗与摊销 | $3.22M | $3.27M | $13.18M | $3.32M | $3.41M |
| 持续经营损益 | $0.00 | $363,000.00 | $49,000.00 | – | – |
| 持续经营净利润 | -$67.26M | -$61.71M | -$222.97M | -$56.74M | -$44.31M |
| 持续经营经营活动现金流净额 | -$57.94M | -$80.39M | -$200.62M | -$48.75M | -$53.18M |
| 投资活动现金流净额 | $33.31M | -$259.93M | $116.77M | -$17.07M | $75.53M |
| 经营活动现金流 | -$57.94M | -$80.39M | -$200.62M | -$48.75M | -$53.18M |
| 债务发行及偿还净额 | -$993,000.00 | -$1.12M | -$8.16M | -$2.42M | -$2.65M |
利润表
| 项目 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| 报告营业总收入 | $6.31M | $7.22M | $31.89M | $10.13M | $8.82M |
| 营业总收入 | $6.31M | $7.22M | $31.89M | $10.13M | $8.82M |
| 营业费用 | $77.93M | $71.34M | $266.96M | $70.28M | $56.97M |
| 销售及管理费用 | $13.60M | $13.52M | $42.26M | $10.55M | $10.15M |
| -管理费用 | $13.60M | $13.52M | $42.26M | $10.55M | $10.15M |
| 研发费用 | $64.33M | $57.81M | $224.70M | $59.74M | $46.83M |
| 营业利润 | -$71.61M | -$64.11M | -$235.07M | -$60.15M | -$48.15M |
| 非经营性利息净收入（支出） | $4.47M | $2.73M | $12.53M | $3.48M | $3.91M |
| 摊薄每股收益 | -$0.52 | -$1.07 | -$2.18 | -$0.63 | -$0.52 |
| 基本每股收益 | -$0.52 | -$1.07 | -$2.18 | -$0.63 | -$0.52 |
| 非经营性利息收入 | $4.63M | $2.91M | $13.66M | $3.79M | $4.28M |
| 非经营性利息支出 | $155,000.00 | $182,000.00 | $1.14M | $307,000.00 | $368,000.00 |
| 其他收入（支出） | -$62,000.00 | -$305,000.00 | -$262,000.00 | -$30,000.00 | -$17,000.00 |
| 证券出售收益 | -$62,000.00 | -$305,000.00 | -$262,000.00 | -$30,000.00 | -$17,000.00 |
| 税前利润 | -$67.20M | -$61.69M | -$222.80M | -$56.70M | -$44.26M |
| 税费 | $53,000.00 | $28,000.00 | $163,000.00 | $44,000.00 | $56,000.00 |
| 净利润 | -$67.26M | -$61.71M | -$222.97M | -$56.74M | -$44.31M |
| 持续经营利润 | -$67.26M | -$61.71M | -$222.97M | -$56.74M | -$44.31M |
| 归属母公司净利润 | -$67.26M | -$61.45M | -$203.15M | -$52.43M | -$41.69M |
| 归属普通股股东净利润 | -$67.26M | -$69.20M | -$249.52M | -$64.02M | -$53.28M |
| 少数股东权益 | $0.00 | -$268,000.00 | -$19.81M | -$4.31M | -$2.63M |
| 优先股股息 | – | $7.75M | $46.37M | $11.59M | $11.59M |
暂无评论——快来第一个聊聊 GENB。
登录后参与讨论。